In a decisive bankruptcy auction, Regeneron Pharmaceuticals secured the core business assets of 23andMe for $256 million. The acquisition, facilitated via court supervision, signals a strategic expansion into genetic testing services as Regeneron aims to bolster its market position in this competitive field.
Back to Top / Monday, May 19, 2025, 8:20 am / permalink 5007 / 7 stories in 9 months
Anglo American Nears $20bn Deal for Teck Resources Acquisition / 5 months
Murdoch succession dispute ends as Lachlan secures media empire control / 5 months
PNC Grows West With $4.1B FirstBank Deal / 5 months
Kraft Heinz to Split Into Two Public Companies / 6 months
Keurig Dr Pepper moves forward with $18B acquisition of JDE Peet’s / 6 months
Soho House to Go Private in $2.7B Transaction / 6 months
Union Pacific and Norfolk Southern Announce $85B Merger Deal / 7 months
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.